BenevolentTech CEO Pesenti: "What the company is doing here is not just the research but putting the drugs through the clinical trials ourselves."
Pharmaceutical companies expend a lot of effort and millions of dollars developing new drugs -- and not the least of their problems is the amount of time spent researching potential advances that turn out to be a blind alley.
BenevolentAI is using artificial intelligence tools to help it wade through millions of pages of drug research, analyse them, and come up with the most promising areas for research.
The company recently appointed Jérôme Pesenti as CEO of its technology division, BenevolentTech.
Previously he was vice president of IBM's Watson Platform, and is now leading a team that is using AI to dramatically accelerate the process of developing new pharmaceuticals.
You have to do clinical trials and go through them.